Groner AC, Brown M. Position of steroid receptor and coregulator mutations in hormone-dependent cancers. J Clin Investig. 2017;127:1126–35.
Tata JR. Signalling via nuclear receptors. Nat Rev Mol Cell Biol. 2002;3:702–10.
Chen Y, Sawyers CL, Scher HI. Focusing on the androgen receptor pathway in prostate most cancers. Curr Opin Pharmacol. 2008;8:440–8.
Furr BJ. The event of Casodex (bicalutamide): preclinical research. Eur Urol. 1996;29:83–95. Suppl 2
Scher HI, Fizazi Okay, Saad F, Taplin ME, Sternberg CN, Miller Okay, et al. Elevated survival with enzalutamide in prostate most cancers after chemotherapy. N. Engl J Med. 2012;367:1187–97.
Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate most cancers earlier than chemotherapy. N. Engl J Med. 2014;371:424–33.
Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. Improvement of a second-generation antiandrogen for remedy of superior prostate most cancers. Science 2009;324:787–90.
Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate most cancers. N. Engl J Med. 2014;371:1028–38.
Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a novel androgen receptor exon generates a constitutively lively androgen receptor that mediates prostate most cancers remedy resistance. Most cancers Res. 2008;68:5469–77.
Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 2013;155:1309–22.
Efstathiou E, Titus M, Wen S, Hoang A, Karlou M, Ashe R, et al. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate most cancers. Eur Urol. 2015;67:53–60.
Li J, Berk M, Alyamani M, Sabharwal N, Goins C, Alvarado J, et al. Hexose-6-phosphate dehydrogenase blockade reverses prostate most cancers drug resistance in xenograft fashions by glucocorticoid inactivation. Sci Translational Med. 2021;13:eabe8226.
Hou Z, Huang S, Li Z. Androgens in prostate most cancers: A story that by no means ends. Most cancers Lett. 2021;516:1–12.
Schneekloth AR, Pucheault M, Tae HS, Crews CM. Focused intracellular protein degradation induced by a small molecule: En path to chemical proteomics. Bioorg Med Chem Lett. 2008;18:5904–8.
Toure M, Crews CM. Small-Molecule PROTACS: New Approaches to Protein Degradation. Angew Chem. 2016;55:1966–73.
Takwale AD, Jo SH, Jeon YU, Kim HS, Shin CH, Lee HK, et al. Design and characterization of cereblon-mediated androgen receptor proteolysis-targeting chimeras. Eur J Med Chem. 2020;208:112769.
Zhao L, Han X, Lu J, McEachern D, Wang S. A extremely potent PROTAC androgen receptor (AR) degrader ARD-61 successfully inhibits AR-positive breast most cancers cell progress in vitro and tumor progress in vivo. Neoplasia 2020;22:522–32.
Han X, Wang C, Qin C, Xiang W, Fernandez-Salas E, Yang CY, et al. Discovery of ARD-69 as a Extremely Potent Proteolysis Focusing on Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Remedy of Prostate Most cancers. J Med Chem. 2019;62:941–64.
Alyamani M, Li Z, Berk M, Li J, Tang J, Upadhyay S, et al. Steroidogenic Metabolism of Galeterone Reveals a Range of Biochemical Actions. Cell Chem Biol. 2017;24:825–32. e6
Ponnusamy S, He Y, Hwang DJ, Thiyagarajan T, Houtman R, Bocharova V, et al. Orally Bioavailable Androgen Receptor Degrader, Potential Subsequent-Era Therapeutic for Enzalutamide-Resistant Prostate Most cancers. Clin Most cancers Res: Off J Am Assoc Most cancers Res. 2019;25:6764–80.
Yang Z, Chang YJ, Yu IC, Yeh S, Wu CC, Miyamoto H, et al. ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype by way of degradation of androgen receptor. Nat Med. 2007;13:348–53.
Hieronymus H, Lamb J, Ross KN, Peng XP, Clement C, Rodina A, et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Most cancers cell. 2006;10:321–30.
Yang H, Chen D, Cui QC, Yuan X, Dou QP. Celastrol, a triterpene extracted from the Chinese language “Thunder of God Vine,” is a potent proteasome inhibitor and suppresses human prostate most cancers progress in nude mice. Most cancers Res. 2006;66:4758–65.
Chadli A, Felts SJ, Wang Q, Sullivan WP, Botuyan MV, Fauq A, et al. Celastrol inhibits Hsp90 chaperoning of steroid receptors by inducing fibrillization of the Co-chaperone p23. J Biol Chem 2010;285:4224–31.
Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complicated features as a ubiquitin-protein ligase within the ubiquitination of p53. Cell 1993;75:495–505.
Huibregtse JM, Scheffner M, Howley PM. Cloning and expression of the cDNA for E6-AP, a protein that mediates the interplay of the human papillomavirus E6 oncoprotein with p53. Mol Cell Biol 1993;13:775–84.
Fang M, Li Y, Ren J, Hu R, Gao X, Chen L. Epilepsy-Related UBE3A Deficiency Downregulates Retinoic Acid Signalling Pathway. Entrance Genet. 2021;12:681295.
Nawaz Z, Lonard DM, Smith CL, Lev-Lehman E, Tsai SY, Tsai MJ, et al. The Angelman syndrome-associated protein, E6-AP, is a coactivator for the nuclear hormone receptor superfamily. Mol Cell Biol. 1999;19:1182–9.
Khan OY, Fu G, Ismail A, Srinivasan S, Cao X, Tu Y, et al. Multifunction steroid receptor coactivator, E6-associated protein, is concerned in growth of the prostate gland. Mol Endocrinol. 2006;20:544–59.
Birch SE, Kench JG, Takano E, Chan P, Chan AL, Chiam Okay, et al. Expression of E6AP and PML predicts for prostate most cancers development and cancer-specific loss of life. Ann Oncol: Off J Eur Soc Med Oncol. 2014;25:2392–7.
Smith CL, DeVera DG, Lamb DJ, Nawaz Z, Jiang YH, Beaudet AL, et al. Genetic ablation of the steroid receptor coactivator-ubiquitin ligase, E6-AP, leads to tissue-selective steroid hormone resistance and defects in replica. Mol Cell Biol. 2002;22:525–35.
Jones JO, An WF, Diamond MI. AR inhibitors recognized by high-throughput microscopy detection of conformational change and subcellular localization. ACS Chem Biol. 2009;4:199–208.
Li H, Ban F, Dalal Okay, Leblanc E, Frewin Okay, Ma D, et al. Discovery of small-molecule inhibitors selectively concentrating on the DNA-binding area of the human androgen receptor. J Med Chem. 2014;57:6458–67.
Zhou Y, Li W, Wang M, Zhang X, Zhang H, Tong X, et al. Aggressive profiling of celastrol targets in human cervical most cancers HeLa cells by way of quantitative chemical proteomics. Mol Biosyst. 2016;13:83–91.
Salminen A, Lehtonen M, Paimela T, Kaarniranta Okay. Celastrol: Molecular targets of Thunder God Vine. Biochemical Biophysical Res Commun. 2010;394:439–42.
Lee JH, Koo TH, Yoon H, Jung HS, Jin HZ, Lee Okay, et al. Inhibition of NF-kappa B activation via concentrating on I kappa B kinase by celastrol, a quinone methide triterpenoid. Biochemical Pharmacol. 2006;72:1311–21.
Search engine marketing HR, Search engine marketing WD, Pyun BJ, Lee BW, Jin YB, Park KH, et al. Radiosensitization by celastrol is mediated by modification of antioxidant thiol molecules. Chem-Biol Work together. 2011;193:34–42.
Hou Z, Huang S, Mei Z, Chen L, Guo J, Gao Y, et al. Inhibiting 3betaHSD1 to remove the oncogenic results of progesterone in prostate most cancers. Cell Rep Med. 2022;3:100561.
Mei Z, Yang T, Liu Y, Gao Y, Hou Z, Zhuang Q, et al. Administration of prostate most cancers by concentrating on 3betaHSD1 after enzalutamide and abiraterone remedy. Cell Rep Med. 2022;3:100608.
Kregel S, Wang C, Han X, Xiao L, Fernandez-Salas E, Bawa P, et al. Androgen receptor degraders overcome frequent resistance mechanisms developed throughout prostate most cancers remedy. Neoplasia 2020;22:111–9.
Proof-of-Idea with PROTACs in Prostate Most cancers. Most cancers Discov. 2020;10:1084. https://doi.org/10.1158/2159-8290.CD-NB2020-054.
Lim HY, Ong PS, Wang L, Goel A, Ding L, Li-Ann Wong A, et al. Celastrol in most cancers remedy: Latest developments, challenges and prospects. Most cancers Lett. 2021;521:252–67.
Shi J, Li J, Xu Z, Chen L, Luo R, Zhang C, et al. Celastrol: A Evaluate of Helpful Methods Overcoming its Limitation in Anticancer Software. Entrance Pharmacol. 2020;11:558741.
Ramamoorthy S, Nawaz Z. E6-associated protein (E6-AP) is a twin operate coactivator of steroid hormone receptors. Nucl Receptor Sign. 2008;6:e006.
Kishino T, Lalande M, Wagstaff J. UBE3A/E6-AP mutations trigger Angelman syndrome. Nat Genet. 1997;15:70–3.
Matsuura T, Sutcliffe JS, Fang P, Galjaard RJ, Jiang YH, Benton CS, et al. De novo truncating mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome. Nat Genet. 1997;15:74–7.
Gao X, Mohsin SK, Gatalica Z, Fu G, Sharma P, Nawaz Z. Decreased expression of e6-associated protein in breast and prostate carcinomas. Endocrinology 2005;146:1707–12.
Jiang YH, Armstrong D, Albrecht U, Atkins CM, Noebels JL, Eichele G, et al. Mutation of the Angelman ubiquitin ligase in mice causes elevated cytoplasmic p53 and deficits of contextual studying and long-term potentiation. Neuron 1998;21:799–811.
Park JH, Partitions JE, Galvez JJ, Kim M, Abate-Shen C, Shen MM, et al. Prostatic intraepithelial neoplasia in genetically engineered mice. Am J Pathol. 2002;161:727–35.
Shaffer PL, Jivan A, Dollins DE, Claessens F, Gewirth DT. Structural foundation of androgen receptor binding to selective androgen response parts. Proc Natl Acad Sci. 2004;101:4758–63.
Xu X, Li C, Gao X, Xia Okay, Guo H, Li Y, et al. Extreme UBE3A dosage impairs retinoic acid signaling and synaptic plasticity in autism spectrum problems. Cell Res. 2018;28:48–68.
